NCT06329258Completed
Combination of Sotyktu and Enstilar for Plaque Psoriasis
A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (Deucravacitinib) in Combination With Enstilar® for Moderate to Severe Plaque Psoriasis
Psoriasis Treatment Center of Central New JerseyPhase 4ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Psoriasis
- Drug/Device/Intervention
- Enstilar
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Psoriasis Treatment Center of Central New Jersey
- Location
- East Windsor, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Dec 06, 2022
- End date
- Nov 13, 2023
- Enrollment
- 30 participants
Primary outcome
Psoriasis Area and Severity Index 75 at week 12
Summary
combination deucravacitinib and enstilar foam
ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06329258
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06329258 through Pure Global AI's free database. This Phase 4 trial is sponsored by Psoriasis Treatment Center of Central New Jersey and is currently Completed. The study focuses on Psoriasis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.